N-Methyl-N-tert.-butyl-4-methoxy-benzylamin | 92111-44-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-Methyl-N-tert.-butyl-4-methoxy-benzylamin
• 英文别名: N-[(4-methoxyphenyl)methyl]-N,2-dimethylpropan-2-amine
• CAS: 92111-44-9
• 化学式: C₁₃H₂₁NO
• 分子量: 207.316
• InChiKey: QHDXSROILBXKPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF
  申请人：INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY

  公开号：US20190031620A1

  公开（公告）日：2019-01-31

  The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

  本发明涉及一种具有HSP90抑制活性或其药用盐的新化合物，以及其药用用途和包含二羟基苯化合物或苯甲酰胺化合物的组合物，该新化合物具有本发明的HSP90抑制活性，可以有效抑制HSP90，因此可以作为用于预防或治疗HSP90介导疾病的药物组合物或用于预防或改善HSP90介导疾病的保健功能食品，所述HSP90介导疾病包括癌症疾病、退行性神经疾病和病毒感染，从而有益地使用。
• C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE
  申请人：Sugimoto Tomohiro

  公开号：US20140046043A1

  公开（公告）日：2014-02-13

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种大环内酯化合物，化学式为（I），对红霉素耐药的细菌有效（例如，耐药的肺炎球菌，链球菌和支原体）。
• Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof
  申请人：INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY

  公开号：US10464907B2

  公开（公告）日：2019-11-05

  The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

  本发明涉及一种具有HSP90抑制活性的新型化合物或其药学上可接受的盐及其药用用途，以及包含二羟基苯基化合物或苯甲酰胺化合物的组合物，该组合物是具有本发明HSP90抑制活性的新型化合物，可有效抑制HSP90、因此可以有效地用作预防或治疗 HSP90 介导的疾病的药物组合物，或用作预防或改善 HSP90 介导的疾病的保健功能食品，这些疾病可从癌症疾病、退行性神经疾病和病毒感染组成的组中选出。
• Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof
  申请人：ONCOZEN CO., LTD.

  公开号：US10889552B2

  公开（公告）日：2021-01-12

  Disclosed is a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

  本发明公开了一种具有HSP90抑制活性的新型化合物或其药学上可接受的盐及其药用用途，以及包含二羟基苯基化合物或苯甲酰胺化合物的组合物，该组合物是一种具有本发明HSP90抑制活性的新型化合物，可有效抑制HSP90、因此可以有效地用作预防或治疗 HSP90 介导的疾病的药物组合物，或用作预防或改善 HSP90 介导的疾病的保健功能食品，这些疾病可从癌症疾病、退行性神经疾病和病毒感染组成的组中选出。
• Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
  申请人：COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US11472807B2

  公开（公告）日：2022-10-18

  Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.

  式(I)化合物 及其与药学上可接受的酸的加成盐，以及向有需要的人施用有效量的该化合物或其任何药学上可接受的盐的方法（作为药物）。